TRIM14 suppressed the progression of NSCLC via hexosamine biosynthesis pathway

Author:

Wei Sisi1,Ai Meiling23,Zhan Yuan4,Yu Jieqing5,Xie Tao2,Hu Qinghua2,Fang Yang2,Huang Xuan2ORCID,Li Yong1ORCID

Affiliation:

1. Department of Anesthesiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University , Nanchang 330006 , China

2. The National Engineering Research Center for Bioengineering Drugs and the Technologies, The Institute of Translational Medicine, Jiangxi Medical College, Nanchang University , Nanchang 330031 , China

3. Department of Pharmacy, Jiangxi Maternal and Child Health Hospital , Nanchang 330006 , China

4. Department of Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University , Nanchang 330006 , China

5. Department of Otorhinolaryngology Head and Neck Surgery, Jiangxi Otorhinolaryngology Head and Neck Surgery Institute, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University , Nanchang 330006 , China

Abstract

Abstract Tripartite Motif 14 (TRIM14) is an oncoprotein that belongs to the E3 ligase TRIM family, which is involved in the progression of various tumors except for non-small cell lung carcinoma (NSCLC). However, little is currently known regarding the function and related mechanisms of TRIM14 in NSCLC. Here, we found that the TRIM14 protein was downregulated in lung adenocarcinoma tissues compared with the adjacent tissues, which can suppress tumor cell proliferation and migration both in vitro and in vivo. Moreover, TRIM14 can directly bind to glutamine fructose-6-phosphate amidotransferase 1 (GFAT1), which in turn results in the degradation of GFAT1 and reduced O-glycosylation levels. GFAT1 is a key enzyme in the rate-limiting step of the hexosamine biosynthetic pathway (HBP). Replenishment of N-acetyl-d-glucosamine can successfully reverse the inhibitory effect of TRIM14 on the NSCLC cell growth and migration as expected. Collectively, our data revealed that TRIM14 suppressed NSCLC cell proliferation and migration through ubiquitination and degradation of GFAT1, providing a new regulatory role for TRIM14 on HBP.

Funder

National Natural Science Foundation of China

Jiangxi Provincial Natural Science Foundation

Publisher

Oxford University Press (OUP)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3